Table 1.
Studies (n) | Sex-specific analysis (n) | Patients (n) | Female (%) | Male-to-female ratio (range) | |
---|---|---|---|---|---|
I. TOTAL | 30 | 1 | 6156 | 41 | 1•4 (0•7–7•0) |
treatment group | 23 | . | 3292 | 40 | 1•5 (0•8–5•0) |
control group | 23 | . | 2757 | 43 | 1•3 (0•5–7•0) |
II. THERAPY GROUPS | |||||
II.I ANTIVIRAL AGENTS | |||||
Viral entry and replication inhibitors | |||||
Remdesivir | 2 | 1 | 1299 | 37 | 1•7 (1•5–1•8) |
treatment group | 2 | . | 699 | 36 | 1•7 (1•3–1•9) |
control group | 2 | . | 600 | 36 | 1•8 (1•7–1•9) |
Lopinavir/ritonavir | 5 | 0 | 460 | 47 | 1•1 (0•7–1•5) |
treatment group | 5 | . | 247 | 46 | 1•2 (0•8–1•6) |
control group | 5 | . | 196 | 47 | 1•1 (0•5–1•4) |
Favipiravir | 1 | 0 | 236 | 53 | 0•9 (-) |
treatment group | 1 | . | 116 | 49 | 1•0 (-) |
control group | 1 | . | 120 | 58 | 0•7 (-) |
Umifenovir | 1 | 0 | 81 | 44 | 1•3 (-) |
treatment group | 1 | . | 45 | 38 | 1•6 (-) |
control group | 1 | . | 36 | 53 | 0•9 (-) |
II.II ANTIMALARIA AGENT | |||||
(hydroxy)chloroquine | 8 | 0 | 3325 | 41 | 1•4 (0•7–2•7) |
treatment group | 8 | . | 1814 | 40 | 1•5 (0•8–3•4) |
control group | 8 | . | 1511 | 43 | 1•3 (0•6–2•1) |
II.III IMMUNE MODULATORS | |||||
Convalescent plasma | 6 | 0 | 75 | 39 | 1•6 (1•0–7•0) |
case series | 5 | . | 54 | 44 | 1•3 (0•8–7•0) |
observational study | 1 | . | 21 | 24 | 3•2 (-) |
treatment group | 1 | . | 6 | 17 | 5•0 (-) |
control group | 1 | . | 15 | 27 | 2•8 (-) |
IL-6 pathway inhibitors | 3 | 0 | 147 | 27 | 2•7 (2•3–6•0) |
treatment group | 1 | . | 42 | 21 | 3•7 (-) |
control group | 1 | . | 69 | 36 | 1•8 (-) |
IL-1 pathway inhibitors | 1 | 0 | 45 | 16 | 5•4 (-) |
treatment group | 1 | . | 29 | 17 | 4•8 (-) |
control group | 1 | . | 16 | 13 | 7•0 (-) |
Corticosteroids | 3 | 0 | 488 | 47 | 1•1 (1•0–1•8) |
treatment group | 3 | . | 294 | 46 | 1•2 (1•1–2•7) |
control group | 3 | . | 194 | 49 | 1•0 (0•9–1•5) |
Data are presented as numbers and percentages.